Global Irbesartan Tablets Market Size By Type (75 mg Tablets, 150 mg Tablets), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Irbesartan Tablets Market was valued at USD 3.2 billion in 2023 and is projected to surpass USD 5.1 billion by 2031, expanding at a CAGR of 6.0% during the forecast period (2023–2031). Irbesartan, an angiotensin II receptor antagonist, is widely prescribed for managing hypertension and diabetic nephropathy. The increasing prevalence of cardiovascular diseases, growing awareness of hypertension management, and the rising geriatric population are key factors fueling market growth. The market is also benefiting from the growing availability of generic alternatives and the increasing integration of irbesartan into combination therapies, enhancing patient compliance and therapeutic outcomes.

Drivers:

Rising Incidence of Hypertension and Chronic Kidney Disease:

The global rise in hypertension and associated complications such as diabetic nephropathy is significantly boosting the demand for irbesartan tablets. According to WHO data, cardiovascular diseases remain the leading cause of death globally, with hypertension being a major contributor.

Favorable Government Initiatives and Health Awareness Campaigns:

Governments worldwide are launching public health initiatives to combat non-communicable diseases. These campaigns are increasing patient awareness and early diagnosis rates, which in turn is driving the uptake of antihypertensive medications like irbesartan.

Increased Availability of Generic Irbesartan:

Patent expirations and the entry of cost-effective generic formulations are improving accessibility, especially in emerging markets. This trend is contributing to broader market penetration and higher prescription volumes.

Restraints:

Adverse Effects and Drug Recalls:

Irbesartan has been subject to recalls in the past due to contamination issues with nitrosamines. These safety concerns can affect consumer confidence and temporarily restrain market growth.

Strict Regulatory Requirements:

Pharmaceutical companies must comply with stringent manufacturing and quality standards for producing irbesartan. These regulatory hurdles can delay product launches and increase operational costs.

Opportunity:

Expansion in Emerging Markets:

Emerging economies in Asia-Pacific and Latin America are witnessing improvements in healthcare infrastructure and increased access to chronic disease medications. This provides a lucrative growth opportunity for irbesartan tablet manufacturers.

Growing Adoption of Fixed-Dose Combinations (FDCs):

The trend toward FDCs in hypertension treatment—combining irbesartan with hydrochlorothiazide or other agents—is gaining popularity for improving therapeutic compliance and effectiveness.

Market by System Type Insights:

Monotherapy Segment Dominates:

As of 2023, the monotherapy segment held the largest market share. Irbesartan as a standalone treatment is commonly prescribed for early-stage hypertension and renal protection in diabetic patients.

Combination Therapy on the Rise:

Combination therapy with hydrochlorothiazide (HCTZ) is expected to witness the fastest growth during the forecast period due to its enhanced efficacy and reduced pill burden, especially for patients with moderate to severe hypertension.

Market by End-use Insights:

Retail Pharmacies Lead Distribution Channels:

Retail pharmacies accounted for the highest revenue share in 2023, driven by widespread consumer access and the dominance of outpatient hypertension management.

Online Pharmacies Gaining Traction:

The online segment is projected to grow rapidly due to rising digital healthcare adoption, especially in urban areas and among tech-savvy populations.

Market by Regional Insights:

North America Dominated in 2023:

North America held the largest market share, supported by a high prevalence of hypertension, robust healthcare infrastructure, and widespread insurance coverage.

Asia-Pacific is the Fastest Growing Market:

Asia-Pacific is forecasted to grow at the highest CAGR due to increasing health awareness, expanding middle-class population, and government-driven healthcare access initiatives in countries like India and China.

Competitive Scenario:

Key players in the global Irbesartan Tablets Market include Sanofi S.A., Teva Pharmaceutical Industries Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Mylan N.V., Macleods Pharmaceuticals Ltd., Aurobindo Pharma, Alembic Pharmaceuticals Ltd., and Zydus Lifesciences Ltd. These companies focus on expanding their geographic reach, product portfolios, and manufacturing capabilities through strategic partnerships, regulatory approvals, and product launches.

Scope of Work – Global Irbesartan Tablets Market

Key Market Developments:

2023: Teva launched a new generic version of irbesartan and hydrochlorothiazide combination tablets in North America.

2024: Lupin Limited expanded its manufacturing facility to enhance production capacity of irbesartan generics for Asian and African markets.

2025: Torrent Pharmaceuticals received FDA approval for its latest combination drug including irbesartan for U.S. distribution.

FAQs:

1) What is the current market size of the Global Irbesartan Tablets Market?

The market size was USD 3.2 billion in 2023.

2) What is the major growth driver of the Global Irbesartan Tablets Market?

The major growth driver is the increasing global burden of hypertension and chronic kidney disease.

3) Which is the largest region during the forecast period in the Global Irbesartan Tablets Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow at the highest rate.

4) Which segment accounted for the largest market share in the Global Irbesartan Tablets Market?

The monotherapy segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Irbesartan Tablets Market?

Key players include Sanofi S.A., Teva, Lupin, Torrent Pharmaceuticals, Aurobindo Pharma, and Zydus Lifesciences.